Each year, the Reagan-Udall Foundation for the FDA conducts an Annual Public Meeting of its Board of Directors to share information about our activities in support of the U.S. Food and Drug Administration. By bringing together a variety of perspectives, the annual public meeting facilitates engagement between FDA and external stakeholders including patients and consumers, regulated industry, health care providers, academics, and others dedicated to improving America's public health. 

It was an opportunity to gain a greater understanding of the FDA's priorities from Robert M. Califf, MD, Commissioner, Food and Drugs, as well as other senior FDA personnel. Attendees heard updates on the Foundation's growing portfolio of activities over the past year from the Foundation leadership. 

In an engaging discussion, Foundation CEO Susan C. Winckler moderated a panel of key FDA leaders as they shared their thoughts on the Agency's ongoing work in a changing regulatory landscape. Panelists touched on topics such as food safety, the FDA's role in innovation of regulated products, and how the agency's various divisions work together to ensure the safety of regulated products.

Dr. Califf highlighted some of the agency's priorities, including  health related mis- and dis-information, and discussed what the agency learned about the development of medical products during the COVID-19 pandemic.